The purpose of this study is to determine if the use of Olaparib for one year is as effective in treating ovarian cancer as the current standard of care treatment and if Olaparib prevents growth and or recurrence.
Thank you for your interest, but this study will start enrolling soon.
United States (Nationwide)
Olivia Lara
Lineberger Comprehensive Cancer Center
Clinical or Medical
Interventional
Cancer (Uterine (endometrial), Ovarian)
Women's Health
25-0174
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
